Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years(COVID-19)
A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Voraussichtlich)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Guifan Li, M.S
- Telefonnummer: +861059613591
- E-Mail: liguifan@biominhai.com
Studienorte
-
-
Hunan
-
Changsha, Hunan, China, 410005
- Hunan Provincial Center for Diseases Control and Prevention
-
Kontakt:
- Tao Huang
- Telefonnummer: +8673184305935
- E-Mail: ymlc01@hncdc.com
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Healthy residents aged 3 to 17 years at the time of consent
- Subjects and/or their guardian agree to sign the informed consent forms voluntarily.
- Be able to comply with study requirements/procedures.
- Axillary temperature ≤ 37.0℃
Exclusion Criteria:
- Within 14 days before vaccination, subjects have been abroad and to villages/communities experienced COVID-19 epidemics, and in contact with COVID-19 cases or suspected cases. Subjects are under isolation observation, or living in the villages/communities with COVID-19 cases or suspected cases;
- Confirmed cases, suspected cases or asymptomatic cases with COVID-19 (refer to Information System of China Disease Prevention and Control);
- Subjects with history of SARS virus infection by self-reported;
- Positive in throat swab through RT-PCR;
- History of vaccination of various COVID-19 vaccines or positive in SARS-CoV-2 antibody test;
- Positive urine pregnancy test for females with menarche
- History of severe allergic reactions (such as acute anaphylaxis, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain) or allergy to known composition of inactivated SARS-CoV-2 vaccine;
- History or family history of convulsion, epilepsy, encephalopathy or mental illness;
- Subjects with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
- Subjects with known or suspected diseases include: severe respiratory diseases, severe cardiovascular diseases, severe liver and kidney diseases, drug-uncontrollable hypertension, diabetic complications, malignant tumors, various acute diseases or acute onset of chronic diseases;
- Diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases;
- History of coagulation dysfunction (e.g. Coagulation factor deficiency, coagulation disease);
- Subjects receiving anti-TB treatment;
- Subjects receiving other research drugs within 6 months before vaccination;
- Subjects receiving immunotherapy or inhibitor therapy within 3 months (consistently oral or infusion for more than 14 days);
- Subjects receiving blood products within 3 months before administration;
- Subjects vaccinated with live attenuated vaccine within 14 days before vaccination;
- Subjects vaccinated with other vaccine within 7 days before vaccination;
- The researchers shall judge the other conditions which might be not in compliance with the requirements of this clinical trial.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
|
2 Dosen Placebo sollten als intramuskuläre Injektion in den lateralen Deltamuskel des Oberarms im Abstand von 28 Tagen verabreicht werden.
|
|
Experimental: Kandidaten-Impfstoff
|
2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated with a 28-day interval constitute a primary immunization course. The third dose on 6 months after primary course is the booster dose. Administer as an intramuscular injection into the lateral deltoid of the upper arm. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Seroconversion rate of SARS-CoV-2 neutralizing antibody
Zeitfenster: 28 days post full primary immunization course
|
28 days post full primary immunization course
|
|
Geometric mean titer of SARS-CoV-2 neutralizing antibody
Zeitfenster: 28 days post full primary immunization course
|
28 days post full primary immunization course
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Auftreten von Nebenwirkungen/Ereignissen
Zeitfenster: 0-28 Tage nach jeder Impfung
|
0-28 Tage nach jeder Impfung
|
|
Serious Adverse Events (SAE)
Zeitfenster: within 12 months post full primary immunization course and the booster dose respectively
|
within 12 months post full primary immunization course and the booster dose respectively
|
|
Seroconversion rate of SARS-CoV-2 IgG binding antibody
Zeitfenster: 28 days post full primary immunization course
|
28 days post full primary immunization course
|
|
Geometric mean titer of SARS-CoV-2 IgG binding antibody
Zeitfenster: 28 days, 3 months, 6 months and 12 months post full primary immunization course
|
28 days, 3 months, 6 months and 12 months post full primary immunization course
|
|
Geometric mean titer of SARS-CoV-2 IgG binding antibody
Zeitfenster: 28 days, 3 months, 6 months and 12 months after the booster dose
|
28 days, 3 months, 6 months and 12 months after the booster dose
|
|
Geometric mean titer of SARS-CoV-2 neutralizing antibody
Zeitfenster: 3 months, 6 months and 12 months post full primary immunization course
|
3 months, 6 months and 12 months post full primary immunization course
|
|
Geometric mean titer of SARS-CoV-2 neutralizing antibody
Zeitfenster: 28 days, 3 months, 6 months and 12 months after the booster dose
|
28 days, 3 months, 6 months and 12 months after the booster dose
|
|
Seropositive rate of SARS-CoV-2 neutralizing antibody
Zeitfenster: 3 months, 6 months and 12 months post full primary immunization course
|
3 months, 6 months and 12 months post full primary immunization course
|
|
Seropositive rate of SARS-CoV-2 neutralizing antibody
Zeitfenster: 28 days, 3 months, 6 months and 12 months after the booster dose
|
28 days, 3 months, 6 months and 12 months after the booster dose
|
|
Seropositive rate of SARS-CoV-2 IgG binding antibody
Zeitfenster: 3 months, 6 months and 12 months post full primary immunization course
|
3 months, 6 months and 12 months post full primary immunization course
|
|
Seropositive rate of SARS-CoV-2 IgG binding antibody
Zeitfenster: 28 days, 3 months, 6 months and 12 months after the booster dose
|
28 days, 3 months, 6 months and 12 months after the booster dose
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Voraussichtlich)
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Primärer Abschluss
Studienabschluss (Voraussichtlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2020L001-2B
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .